Stay updated with breaking news from Relations Communication Manager. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis
POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic
Regulatory News: POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology,
(0) POXEL SA (Euronext POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) today announced the publication of the meeting notice for the Annual General Meeting, which will take place in a closed virtual session on June 23 rd, 2021 at 1.00pm CEST. In the context of the COVID-19 pandemic and in accordance with the regulations introduced to limit or prohibit travel and collective gatherings to prevent the spread of the COVID-19 virus (article 4 of Order...
Poxel SA: Poxel Announces Participation at Upcoming Virtual Investor Conferences in June POXEL SA (Euronext POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its participation at upcoming virtual investor conferences in June 2021. Thomas Kuhn, CEO, will present the company and Poxel management team members will be available for one-on-one virtual meetings. Jefferies Global Healthcare Conference st from 11:00 am to 11:25 am ET. JMP ...